rs367545984
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM1
The NM_000551.4(VHL):c.556G>A(p.Glu186Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000235 in 1,614,050 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.000039 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000022 ( 0 hom. )
Consequence
VHL
NM_000551.4 missense
NM_000551.4 missense
Scores
7
10
2
Clinical Significance
Conservation
PhyloP100: 7.78
Genes affected
VHL (HGNC:12687): (von Hippel-Lindau tumor suppressor) This gene encodes a component of a ubiquitination complex. The encoded protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. In addition to oxygen-related gene expression, this protein plays a role in many other cellular processes including cilia formation, cytokine signaling, regulation of senescence, and formation of the extracellular matrix. Variants of this gene are associated with von Hippel-Lindau syndrome, pheochromocytoma, erythrocytosis, renal cell carcinoma, and cerebellar hemangioblastoma. [provided by RefSeq, Jun 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM1
In a chain von Hippel-Lindau disease tumor suppressor (size 212) in uniprot entity VHL_HUMAN there are 96 pathogenic changes around while only 8 benign (92%) in NM_000551.4
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VHL | NM_000551.4 | c.556G>A | p.Glu186Lys | missense_variant | 3/3 | ENST00000256474.3 | NP_000542.1 | |
VHL | NM_198156.3 | c.433G>A | p.Glu145Lys | missense_variant | 2/2 | NP_937799.1 | ||
VHL | NM_001354723.2 | c.*110G>A | 3_prime_UTR_variant | 3/3 | NP_001341652.1 | |||
VHL | NR_176335.1 | n.885G>A | non_coding_transcript_exon_variant | 4/4 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152172Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
6
AN:
152172
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251418Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135906
GnomAD3 exomes
AF:
AC:
4
AN:
251418
Hom.:
AF XY:
AC XY:
3
AN XY:
135906
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000219 AC: 32AN: 1461878Hom.: 0 Cov.: 30 AF XY: 0.0000165 AC XY: 12AN XY: 727242
GnomAD4 exome
AF:
AC:
32
AN:
1461878
Hom.:
Cov.:
30
AF XY:
AC XY:
12
AN XY:
727242
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152172Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74334
GnomAD4 genome
AF:
AC:
6
AN:
152172
Hom.:
Cov.:
32
AF XY:
AC XY:
3
AN XY:
74334
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
2
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:4
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jan 18, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 23, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 04, 2016 | Variant summary: Variant affects a conserved nucleotide and result in replacement of a medium size and acidic Glutamic acid (E) with a large size and basic Lysine (K). 3/4 in silico tools predict the variant to be disease causing. It was observed in the Non-Finnish European subcohort of the ExAC project at an allele frequency of 0.003% which exceeds the maximal expected allele frequency of a disease causing VHL variant (0.002). However, the variant was identified in only 2 individuals; therefore the significance of these observations is uncertain. The variant was reported in a Korean family in which the variant carriers presented with Angioma, hemangioblastoma of the brain and renal cell carcinoma (Chen_HumMutat_1995). Additional patients with Type I disease were also reported to carry the variants, however these reports lack information about the prevalence of the variant in healthy individuals, therefore association between the variant and the disease remains uncertain (Stolle_HumMutat_1998, Hwang_JHG_2014, Zbar_HumMutat_1996). HGMD lists variant affecting the same codon c.556G>G (p.E186X) and variants in the close proximity of the variant of interest c.555C>A and c.555C>G (p.Y185X) indicating the variant to be located in a mutational hotspot and suggesting pathogenicity. However, a clinical laboratory classify variant as Uncertain via ClinVar (without evidence to independently evaluate). Considering all evidence, the variant is classified as VUS-possibly pathogenic until more information becomes available. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 29, 2024 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Also known as c.769G>A, p.E257K; This variant is associated with the following publications: (PMID: 14722919, 8956040, 18836774, 10408776, 9681856, 25637381, 25078357, 20151405, 9829911, 7728151, 28753842, 33102977, Dwivedi2022[Article]) - |
Von Hippel-Lindau syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | Dec 31, 2023 | - - |
Uncertain significance, no assertion criteria provided | research | CSER _CC_NCGL, University of Washington | Jun 01, 2014 | - - |
Chuvash polycythemia Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 17, 2024 | - - |
Von Hippel-Lindau syndrome;C1837915:Chuvash polycythemia Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 27, 2024 | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 186 of the VHL protein (p.Glu186Lys). This variant is present in population databases (rs367545984, gnomAD 0.01%). This missense change has been observed in individuals with von Hippel-Lindau syndrome (PMID: 7728151, 25078357). This variant is also known as 769G>T(p.Glu186Lys). ClinVar contains an entry for this variant (Variation ID: 161403). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt VHL protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 20, 2024 | The p.E186K variant (also known as c.556G>A), located in coding exon 3 of the VHL gene, results from a G to A substitution at nucleotide position 556. The glutamic acid at codon 186 is replaced by lysine, an amino acid with similar properties. This alteration has been detected in a von Hippel-Lindau (VHL) family affected with retinal angiomas, CNS hemangioblastoma, and renal cell cancer but not pheochromocytomas (Chen F et al. Hum Mutat. 1995;5(1):66-75). This alteration has also been observed in an exome cohort in an unaffected individual (Amendola LM et al. Genome Res. 2015 Mar;25(3):305-15). Of note, this alteration is also known as 769G>A in published literature. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. - |
Von Hippel-Lindau syndrome;C0031511:Pheochromocytoma;C1837915:Chuvash polycythemia;CN074294:Nonpapillary renal cell carcinoma Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 30, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Pathogenic
DEOGEN2
Pathogenic
D;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D
M_CAP
Pathogenic
D
MetaRNN
Uncertain
D;D
MetaSVM
Pathogenic
D
MutationAssessor
Benign
M;.
PrimateAI
Uncertain
T
PROVEAN
Uncertain
N;N
REVEL
Pathogenic
Sift
Uncertain
.;D
Sift4G
Uncertain
D;D
Polyphen
D;D
Vest4
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at